Lör 2 mar / År 42 / Nr 5 2023

Timeline Bioresearch notes

Timeline Bioresearch is an independent contract research organization specializing in preclinical pharmacology. The company has scientific expertise and long experience in conducting in vivo pharmacokinetic studies, and can provide custom-tailored solutions for specific needs

Timeline Bioresearch, based in Medicon Valley in Sweden, was founded five years ago as a preclinical, in vivo contract research organisation, created to support big pharma and biotech companies and academic groups seeking help with the early stages of drug development. The company is based in the former AstraZeneca facilities, which provide infrastructure, office space and laboratories, and has ten employees.
Focusing on research pharmacology and in vivo drug characterization, Timeline Bioresearch grew out of the Danish company Pipeline Biotech, which was founded in 1999.
“We work to establish relationships and partner with our clients, on both a short-term and long-term basis. We see ourselves as part of our customer’s internal research departments,” said Klaus Kristensen, CEO. “We have worked with some customers for over two decades.”

Working in partnership
Timeline Bioresearch’s expertise lies within preclinical pharmacology in cancer, inflammation and diabetes, with a particular focus on toxicity, pharmacokinetics, and efficacy testing. The company can work with small molecules, biologics including antibodies, and more complex products such as nanoparticles.
“We pride ourselves on providing highly-consistent quality data, and on being reliable, and timely,” said Kristensen. “As a small CRO we can be flexible, including providing customised solutions to meet our clients’ specific needs.”
Early-stage toxicology studies provide a cost-effective and quick way to help research teams to identify which compounds are unlikely to succeed in further development. Timeline Bioresearch’s approach is to administer a number of compounds to small numbers of rats or mice to provide an idea of relative toxicity and effect, and to support the selection of potential candidates. Drug metabolism and pharmacokinetic (DMPK) studies further support candidate selection.

From the small to the large: Timeline Bioresearch’s animal models
Once a research team has selected a number of candidates, the next step is to evaluate efficacy. Timeline Bioresearch works with a wide variety of different disease models, from anti-haemostatis to wound healing and from mice to pigs.
“Our animal models include well-known disease models that are frequently used in research, as well as models specifically designed and customised for special projects,” said Kristensen. “We can validate these models using standards based on the steps used in GMP validation.”
One of the things that sets Timeline Bioresearch apart from other preclinical CROs is its use of pigs, both minipigs and full-size animals. Pigs are closer to humans than the other commonly-used large animal, the beagle, both anatomically and physiologically. in many aspects. Organs such as the heart and kidney are similar in size and anatomy, and pigs are omnivores, with similar metabolism.